- Home
- CHRS vs ENX Comparison
CHRS vs ENX Comparison
Compare CHRS & ENX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHRS
- ENX
- Stock Information
- Founded
- CHRS 2010
- ENX 2002
- Country
- CHRS United States
- ENX United States
- Employees
- CHRS 235
- ENX N/A
- Industry
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- ENX Finance/Investors Services
- Sector
- CHRS Health Care
- ENX Finance
- Exchange
- CHRS Nasdaq
- ENX Nasdaq
- Market Cap
- CHRS 134.4M
- ENX 175.5M
- IPO Year
- CHRS 2014
- ENX N/A
- Fundamental
- Price
- CHRS $1.16
- ENX $9.70
- Analyst Decision
- CHRS Strong Buy
- ENX
- Analyst Count
- CHRS 4
- ENX 0
- Target Price
- CHRS $5.38
- ENX N/A
- AVG Volume (30 Days)
- CHRS 2.4M
- ENX 25.4K
- Earning Date
- CHRS 03-12-2025
- ENX 01-01-0001
- Dividend Yield
- CHRS N/A
- ENX 3.94%
- EPS Growth
- CHRS N/A
- ENX N/A
- EPS
- CHRS N/A
- ENX 0.16
- Revenue
- CHRS $304,340,000.00
- ENX N/A
- Revenue This Year
- CHRS $2.47
- ENX N/A
- Revenue Next Year
- CHRS N/A
- ENX N/A
- P/E Ratio
- CHRS N/A
- ENX $61.00
- Revenue Growth
- CHRS 44.19
- ENX N/A
- 52 Week Low
- CHRS $0.66
- ENX $7.84
- 52 Week High
- CHRS $2.87
- ENX $10.07
- Technical
- Relative Strength Index (RSI)
- CHRS 38.01
- ENX 56.12
- Support Level
- CHRS $1.03
- ENX $9.56
- Resistance Level
- CHRS $1.39
- ENX $9.70
- Average True Range (ATR)
- CHRS 0.14
- ENX 0.09
- MACD
- CHRS -0.03
- ENX 0.02
- Stochastic Oscillator
- CHRS 14.04
- ENX 96.30
About CHRS Coherus BioSciences Inc.
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.
About ENX Eaton Vance New York Municipal Bond Fund of Beneficial Interest $.01 par value
Eaton Vance New York Municipal Bond Fund is principally engaged in managing investment funds and providing investment management and advisory services to high-net-worth individuals and institutions. It is a non-diversified, closed-end investment company. Its objective is to provide current income exempt from regular federal income tax, including alternative minimum tax, and, in state specific funds, taxes in specified state.